ANGO AngioDynamics, Inc.
XNAS
12.18
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ANGO
$12.18
—
Key stats
$12.18
Pre-market
$12.22
+0.41%
- 52-Week Range
- $9.39 – $16.29
- YTD
- -3.98%
- IV Rank (30D)
- 7.45
- Straddle Price
- $1.90
- P/C Vol Ratio
- 0.04
- Market Cap
- $0.5B
- Open
- $12.32
- Day Range
- $12.14 – $12.39
- Volume
- 458,832
- Prev Close
- $12.37
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.55 |
| Cost of Equity (CAPM) | 7.69% (VRP-adj) |
| WACC | 7.89% |
| Volatility Risk Premium | +68.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +1.9% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.02 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -20.1% |
| Book / Price | 32.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 55.7% |
| FCF Margin (TTM) | -0.4% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $14.48 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $12.80 |
| Bollinger Width / SMA20 | 419.3% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $1B |
Peers used for multiples: ABT, BDX, GEHC, MDT, SYK
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
45%
20-Day Fair Value
≈ by Nov 25, 2026
$12.21
α +0.4%
rank 88%
conviction
24%
40-Day Fair Value
≈ by Dec 24, 2026
$12.38
α +1.7%
rank 89%
conviction
57%
60-Day Fair Value
≈ by Jan 22, 2027
$12.33
α +1.3%
rank 89%
conviction
45%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 31.6× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 14.8× · 5 peers |
| Peer P/B | $11.55 | 50% | median 2.9× · 5 peers |
| Peer P/S | $25.81 | 50% | median 3.2× · 5 peers |
| Market Anchor (SMA50) | $14.48 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $11.73 | 0% | 5 strikes · skew -0.84 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- Employees
- 632
- List Date
- 2004-05-27
- CIK
- 0001275187
- Headquarters
- Latham, NY
- Homepage
- https://www.angiodynamics.com
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 21.37% | -25.82% | -2.62% | -26.53% | 27.06% | -18.30% | -4.14% |
| Feb | 10.73% | 10.42% | -7.34% | -8.65% | -15.85% | 9.79% | -0.15% |
| Mar | 10.07% | -10.18% | -17.41% | 6.73% | 0.75% | 0.09% | -1.66% |
| Apr | 4.97% | -6.53% | -15.79% | -0.69% | -3.83% | -8.38% | -5.04% |
| May | -6.13% | -7.05% | 10.00% | 8.98% | 10.99% | 2.87% | 3.28% |
| Jun | 15.50% | -1.63% | 8.20% | -5.47% | 2.27% | 19.25% | 6.35% |
| Jul | -2.77% | 16.12% | -15.79% | 37.06% | -6.93% | 13.07% | 6.79% |
| Aug | 4.93% | -4.98% | -6.63% | -4.24% | 19.86% | 6.33% | 2.54% |
| Sep | -11.16% | -5.01% | -5.43% | 6.28% | 6.79% | -3.03% | -1.93% |
| Oct | 8.75% | -30.97% | -16.67% | -12.32% | 8.67% | -19.51%* | -10.34% |
| Nov | -12.33% | -8.03% | 4.48% | 3.74% | 4.82% | -- | -1.46% |
| Dec | 8.20% | 8.17% | 14.29% | 28.29% | -1.00% | -- | 11.59% |
| Total | 57.41% | -54.74% | -44.74% | 19.29% | 57.97% | -5.31% | 4.98% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $12.80
SMA 50: $14.48
SMA 200: $12.43
Current: $12.17
EMA 12: $12.18
EMA 26: $12.99
MACD: -0.8156 | Signal: 0.0859
BEARISH
ADX (14): 41.03
STRONG TREND
+DI: 14.89
−DI: 26.60
Momentum Oscillators
RSI (14): 39.93
NEUTRAL
Stoch %K: 34.10
Stoch %D: 29.63
Williams %R: -60.15
Volume & Volatility
BB Upper: $16.23
BB Lower: $9.36
NEUTRAL
OBV: 15,219,812
Vol SMA 20: 1,089,927
Vol ROC: -57.64%
ATR: $0.65
True Range: $0.25
HV 20: 94.7%
HV 30: 77.9%
HV 60: 57.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is the LLM Stock Analysis Report for ANGO:
Executive Summary
BULLISH (Confidence Level: 7/10)
- Key drivers: Technical indicators, options metrics, market data, recent news headlines (no available)
- Primary risks: Moderate volatility, earnings miss potential
- Investment thesis: ANGO's current price is trading near the middle Bollinger Band, indicating a neutral momentum. The MACD signal line crossover suggests bullish momentum.
- Recent news sentiment impact: No recent news headlines available; however, this lack of recent news could be interpreted as a positive sign, as it may indicate limited market volatility.
Technical Analysis
Trend Direction: Neutral (short-term), Bullish (medium-term)
- Support/Resistance Levels: Middle Bollinger Band ($11.15) and the EMA 26 ($11.05)
- Momentum Signals:
- RSI interpretation: Neutral (60.35) - not overbought or oversold
- MACD signal line crossover: Bullish momentum
- Bollinger Bands position: Neutral, with price near the middle band
- Volume Analysis: Moderate volume flow (629033.20), with a slight bias towards calls (26 vs 14 puts)
News & Sentiment Analysis
Recent Headlines Summary: No recent news headlines available
- Sentiment Assessment: Neutral (no recent news)
- Catalyst Identification: Upcoming earnings release (2026-01-01) and product launches in the near future
- Market Narrative: The lack of recent news may be a positive sign, indicating limited market volatility.
Risk & Volatility Assessment
Beta Interpretation: Moderate risk relative to market (beta 0.99)
- Volatility Regime: Moderate volatility - stock generally follows market
- Options Market Signals:
- IV Rank: Medium (25.5%)
- Put/Call Volume Ratio: Bullish sentiment (0.54)
- Open Interest: More calls than puts (483 vs 94)
- Downside Protection: Support levels are the middle Bollinger Band ($11.15) and the EMA 26 ($11.05)
Market Context & Positioning
Sector Performance: ANGO's sector is relatively strong, with a positive correlation to the overall market
- Institutional Activity: Moderate volume flow (629033.20) suggests institutional interest
- Correlation Analysis: ANGO has a moderate correlation (0.30) to the overall market
- Relative Valuation: ANGO's current price is trading near the middle Bollinger Band, indicating a neutral momentum.
Key Levels & Action Items
Critical Price Levels:
-
Middle Bollinger Band ($11.15)
-
EMA 26 ($11.05)
-
Breakout/Breakdown Levels:
- Upper Bollinger Band ($11.91) - potential resistance
- Lower Bollinger Band ($10.40) - potential support
-
Time-Sensitive Catalysts: Upcoming earnings release (2026-01-01)
-
Risk Management: Monitor volume and price action; adjust stop-loss levels and position sizing as needed.
Please note that this report is based solely on the provided data, without considering any external factors or market conditions.
Generated
News
All ANGO news →
Medtech segment surges 13.2% as NanoKnife prostate procedures hit record volumes.
AngioDynamics beats earnings, and drops 20%.
Showing 1–10 of 11
Page 1 of 2
Earnings History
20 of 23 under expected move
Avg Expected Move
13.55%
Avg Actual Move
6.57%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-07 | After-Close | 7.81% | 0.03% | 0.00x | Within |
| 2021-03-30 | After-Close | 7.57% | 4.14% | 0.55x | Within |
| 2021-07-13 | After-Close | 11.01% | 3.68% | 0.33x | Within |
| 2021-09-30 | After-Close | 12.14% | 1.39% | 0.11x | Within |
| 2022-01-06 | After-Close | 9.40% | 4.21% | 0.45x | Within |
| 2022-04-07 | After-Close | 9.66% | 0.72% | 0.07x | Within |
| 2022-07-12 | After-Close | 4.40% | 4.50% | 1.02x | Exceeded |
| 2022-10-06 | After-Close | 12.11% | 8.30% | 0.69x | Within |
| 2023-03-30 | After-Close | 22.53% | 13.63% | 0.60x | Within |
| 2023-07-12 | After-Close | 5.94% | 0.82% | 0.14x | Within |
| 2023-10-04 | After-Close | 8.24% | 3.38% | 0.41x | Within |
| 2024-01-05 | After-Close | 20.93% | 2.74% | 0.13x | Within |
| 2024-04-04 | After-Close | 41.09% | 9.84% | 0.24x | Within |
| 2024-07-16 | Pre-Market | 18.97% | 26.64% | 1.40x | Exceeded |
| 2024-10-03 | After-Close | 16.09% | 4.24% | 0.26x | Within |
| 2025-01-08 | After-Close | 7.73% | 4.95% | 0.64x | Within |
| 2025-04-02 | After-Close | 14.04% | 9.58% | 0.68x | Within |
| 2025-07-15 | Pre-Market | 19.73% | 10.18% | 0.52x | Within |
| 2025-10-02 | Pre-Market | 17.62% | 6.05% | 0.34x | Within |
| 2026-01-06 | Pre-Market | 15.68% | 13.53% | 0.86x | Within |
| 2026-04-02 | After-Close | 8.49% | 4.56% | 0.54x | Within |
| 2026-07-14 | After-Close | 8.27% | 11.31% | 1.37x | Exceeded |
| 2026-10-08 | After-Close | 12.24% | 2.58% | 0.21x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ANGO Options Activity & IV Rank
ANGO IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 47.6%
7-DTE IV: —
Expected Move: $1.90
7-DTE Move: $1.90
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 187
Put Volume: 7
P/C Volume: 0.037
BULLISH
Call OI: 197
Put OI: 1
P/C OI: 0.005
Total OI: 198
ATM Options Pricing
ATM Call: $0.35
ATM Put: $1.55
Call %: 2.9%
Put %: 12.7%
Chain Summary
Chain Volume: 479
Chain OI: 862
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 45th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
45%
vs own history
GEX tilt
+0.58
OI-weighted, today
Vanna tilt
+0.50
δ-sensitivity to IV
Charm tilt
-0.56
δ-decay vs time
Vanna tilt +0.50: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.56: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 134.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)7.5LowOct 26
Straddle Price (30 DTE)$1.90Oct 26
Beta Analysis
Risk Metrics
Beta: 1.0006
Alpha: -2.59%
Correlation: 0.2662
R-Squared: 7.1%
Stock Volatility: 47.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own ANGO
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $39.8M | #386 of 1945 | -3.7% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $10.2M | #1559 of 3716 | +21.5% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $9.5M | #1077 of 3138 | -8.6% | 13F | |
| Citadel Hedge fund Ken Griffin | $162K | #5580 of 6285 | -74.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $4K | #4289 of 4729 | -52.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ANGO Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 41,737,697 (as of 2026-08-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$425.88K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Wolverine Trading, LLC Custodian | $250.24K | 58.76% | 2025-09-30 |
| 2 | IMC-Chicago, LLC Custodian | $169.13K | 39.71% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $6.50K | 1.53% | 2026-06-30 |
2 filers$121.88K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Wolverine Trading, LLC Custodian | $112.77K | 92.53% | 2025-09-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $9.11K | 7.47% | 2026-06-30 |
ANGO Insider Trading (Form 4)
Latest: 2026-07-31Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Warren Nighan JR | SVP Quality and Regulatory | Sell (S) | −23,370 | $14.72 | -$344.0K | EDGAR |
| 2026-07-24 | Chad Thomas Campbell | SVP/GM, Vascular Access | Mixed | +4,136 | $13.82 | -$32.2K | EDGAR |
| 2026-07-24 | Laura Piccinini | SVP International | Mixed | +3,541 | $13.82 | -$62.3K | EDGAR |
| 2026-07-24 | James C Clemmer | President and CEO | Mixed | +25,630 | $13.82 | -$369.4K | EDGAR |
| 2026-07-24 | Stephen A Trowbridge | EVP and CFO | Mixed | +7,977 | $13.82 | -$115.0K | EDGAR |
| 2026-07-24 | Warren Nighan JR | SVP Quality and Regulatory | Mixed | +4,023 | $13.82 | -$23.1K | EDGAR |
| 2026-07-22 | Wesley Johnson | Director | Award (A) | +11,887 | — | EDGAR | |
| 2026-07-22 | Michael E Tarnoff | Director | Award (A) | +11,887 | — | EDGAR | |
| 2026-07-22 | Stephen A Trowbridge | EVP and CFO | Award (A) | +53,257 | — | EDGAR | |
| 2026-07-22 | Lawrence T Weiss | SVP, Chief Legal Officer | Award (A) | +21,288 | — | EDGAR | |
| 2026-07-22 | Warren Nighan JR | SVP Quality and Regulatory | Award (A) | +17,966 | — | EDGAR | |
| 2026-07-22 | Eileen O'Shea Auen | Director | Award (A) | +11,887 | — | EDGAR | |
| 2026-07-22 | Chad Thomas Campbell | SVP/GM, Vascular Access | Award (A) | +16,081 | — | EDGAR | |
| 2026-07-22 | Howard W Donnelly | Director | Award (A) | +11,887 | — | EDGAR | |
| 2026-07-22 | Lorinda Burgess | Director | Award (A) | +11,887 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ANGO Insider Holdings
13 insiders · @ $12.17
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | James C Clemmer | President and CEO | 862,448 | $10.50M | $0 | 2 | 2026-07-24 |
| 2 | Stephen A Trowbridge | EVP and CFO | 314,115 | $3.82M | $0 | 3 | 2026-07-24 |
| 3 | Howard W Donnelly | Director | 178,938 | $2.18M | $0 | 1 | 2026-07-22 |
| 4 | Wesley Johnson | Director | 155,425 | $1.89M | $0 | 1 | 2026-07-22 |
| 5 | Jan Stern Reed | Director | 116,921 | $1.42M | $0 | 1 | 2026-07-22 |
| 6 | Eileen O'Shea Auen | Director | 116,605 | $1.42M | $0 | 1 | 2026-07-22 |
| 7 | Lawrence T Weiss | SVP, Chief Legal Officer | 112,618 | $1.37M | $0 | 2 | 2026-07-22 |
| 8 | Chad Thomas Campbell | SVP/GM, Vascular Access | 108,676 | $1.32M | $0 | 3 | 2026-07-24 |
| 9 | Karen A Licitra | Director | 102,322 | $1.25M | $0 | 1 | 2026-07-22 |
| 10 | Michael E Tarnoff | Director | 95,265 | $1.16M | $0 | 1 | 2026-07-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ANGO Board & Officers
As of SEC filings through Jul 31, 2026Directors 8
- Howard W Donnelly · on file since 2006
- Wesley Johnson · since Jan 29, 2007
- James C Clemmer · since Apr 1, 2016
- Eileen O'Shea Auen · since Nov 6, 2016
- Jan Stern Reed · since Nov 6, 2016
- Karen A Licitra · since Jul 17, 2019
- Michael E Tarnoff · since Oct 15, 2019
- Lorinda Burgess · since Jul 19, 2023
Officers 6
- James C Clemmer · President and CEO · since Apr 1, 2016
- Stephen A Trowbridge · EVP and CFO · listed since Jul 2020
- Lawrence T Weiss · SVP, Chief Legal Officer · since Dec 2, 2024
- Chad Thomas Campbell · SVP/GM, Vascular Access · since Apr 26, 2017
- Laura Piccinini · SVP International · since Jul 21, 2021
- Warren Nighan JR · SVP Quality and Regulatory · since Sep 22, 2021
Changes in the last 10 years (25)
| Dec 2, 2024 | Lawrence T Weiss became SVP, Chief Legal Officer |
| Jan 16, 2024 | The company announced the departure of Dennis S Meteny from the board in an SEC filing |
| Dec 29, 2023 | The company announced the departure of Dave Helsel as SVP Global Operations and R&D in an SEC filing |
| Jul 19, 2023 | Lorinda Burgess became a director |
| Dec 30, 2021 | Scott Centea listed as Svp/gm, Vit (previously Sr. VP/GM, Global VIT) in SEC filings |
| Sep 22, 2021 | Warren Nighan JR became SVP Quality and Regulatory |
| Jul 27, 2021 | Scott Centea listed as Sr. VP/GM, Global VIT (previously Svp/gm, Vit) in SEC filings |
| Jul 21, 2021 | Laura Piccinini became SVP International |
| Feb 1, 2021 | Richard C Rosenzweig became SVP and General Counsel |
| Sep 3, 2020 | Scott Centea became Svp/gm, Vit |
| Jul 17, 2020 | Stephen A Trowbridge listed as EVP and CFO (previously SVP and General Counsel) in SEC filings |
| Oct 15, 2019 | Michael E Tarnoff became a director |
| Jul 17, 2019 | Karen A Licitra became a director |
| Jan 23, 2019 | Dave Helsel became SVP Global Operations and R&D |
| Jan 23, 2019 | Brent J. Boucher became SVP and GM of Oncology |
| Apr 26, 2017 | Robert Arthur Simpson became SVP/GM, Global Vascular |
| Apr 26, 2017 | Chad Thomas Campbell became SVP/GM, Vascular Access |
| Apr 14, 2017 | Navilyst Medical Co-Invest, LLC reported in an SEC filing no longer being a 10% owner |
| Apr 14, 2017 | David F Burgstahler reported in an SEC filing no longer being a director |
| Apr 14, 2017 | David F Burgstahler reported in an SEC filing no longer being a 10% owner |
| Apr 14, 2017 | Avista Capital Partners, L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 14, 2017 | Avista Capital Partners GP, LLC reported in an SEC filing no longer being a 10% owner |
| Apr 14, 2017 | Avista Capital Partners (Offshore), L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 6, 2016 | Jan Stern Reed became a director |
| Nov 6, 2016 | Eileen O'Shea Auen became a director |
Not reported recently (9)
- Scott Centea · Last reported as Svp/gm, Vit in an SEC filing dated Sep 21, 2023
- Richard C Rosenzweig · Last reported as SVP and General Counsel in an SEC filing dated Feb 7, 2023
- Kevin J Gould · Last reported as a director in an SEC filing dated Jul 16, 2020
- Brent J. Boucher · Last reported as SVP and GM of Oncology in an SEC filing dated Feb 18, 2020
- Michael Greiner · Last reported as EVP and CFO in an SEC filing dated Oct 18, 2019
- Robert Arthur Simpson · Last reported as SVP/GM, Global Vascular in an SEC filing dated Aug 19, 2019
- Jeffrey Gold · Last reported as a director in an SEC filing dated Jul 19, 2019
- Steve LaPorte · Last reported as a director in an SEC filing dated Jul 20, 2018
- Stark Richard · Last reported as SVP, GM - Oncology in an SEC filing dated Nov 17, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ANGO Proposed Insider Sales (Form 144)
Latest: 2026-07-30
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $344K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
WARREN NIGHAN (1, $344K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | WARREN NIGHAN | Officer | 23,370 | $344.0K | 2026-07-30 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-01-16 | Nighan Warren JR | Officer | 4,060 | $50.0K | 2025-01-16 | MORGAN STANLEY SMITH BARNEY LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
45 ETFs hold ANGO
25 shown · $69.41M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $19.2M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $11.5M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $6.6M | — | 2026-09-30 |
| 4 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $4.0M | — | 2026-10-23 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.3M | — | 2026-09-30 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $3.3M | $13.9B | 2026-10-23 |
| 7 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.4M | — | 2026-10-23 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $2.3M | — | 2026-05-31 |
| 9 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 0.06% | $2.2M | $3.6B | 2026-10-23 |
| 10 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.8M | — | 2026-10-23 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.7M | — | 2026-09-30 |
| 12 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.02% | $1.5M | $6.6B | 2026-10-23 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.11% | $1.4M | $1.2B | 2026-10-23 |
| 14 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.04% | $1.1M | $3.2B | 2026-10-23 |
| 15 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.0M | $96.5B | 2026-10-23 |
| 16 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.04% | $1.0M | — | 2026-07-31 |
| 17 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $927,931 | $13.7B | 2026-10-23 |
| 18 | XHE State Street® SPDR® S&P® Health Care Equipment ETF | SPDR (State Street) | 0.55% | $836,060 | $151.1M | 2026-10-23 |
| 19 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.07% | $763,910 | $1.0B | 2026-10-23 |
| 20 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $737,189 | — | 2026-10-23 |
| 21 | VFMF Vanguard U.S. Multifactor ETF | Vanguard | 0.06% | $624,160 | — | 2026-10-23 |
| 22 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.03% | $404,463 | — | 2026-09-30 |
| 23 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $264,476 | — | 2026-05-31 |
| 24 | SMLV State Street® SPDR® US Small Cap Low Volatility Index ETF | SPDR (State Street) | 0.10% | $249,801 | $257.2M | 2026-10-23 |
| 25 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $217,965 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.78
TTM Revenue
$325.38M
TTM Net Income
$-32.94M
TTM Op. Cash Flow
$3.67M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '27 | 2026-08-31 | $80.92M | $-7.10M | $-0.17 | $-15.33M |
| Q4 '26 | 2026-05-31 | $86.61M | $-11.40M | $-0.27 | $17.45M |
| Q3 '26 | 2026-02-28 | $78.42M | $-8.08M | $-0.19 | $-3.11M |
| Q2 '26 | 2025-11-30 | $79.43M | $-6.35M | $-0.15 | $4.66M |
| Q1 '26 | 2025-08-31 | $75.71M | $-10.90M | $-0.26 | $-15.91M |
| Q4 '25 | 2025-05-31 | $80.16M | $-6.05M | $-0.15 | $18.81M |
| Q3 '25 | 2025-02-28 | $72.00M | $-4.41M | $-0.11 | $-13.16M |
| Q2 '25 | 2024-11-30 | $72.84M | $-10.74M | $-0.26 | $2.47M |
| Q1 '25 | 2024-08-31 | $67.49M | $-12.80M | $-0.31 | $-18.25M |
| Q4 '24 | 2024-05-31 | $70.98M | $-13.45M | $-0.33 | $5.00M |
| Q3 '24 | 2024-02-29 | $75.18M | $-187.74M | $-4.67 | $-12.44M |
| Q2 '24 | 2023-11-30 | $79.07M | $-29.05M | $-0.72 | $5.17M |
Q1 2027 • period ending 2026-08-31 • filed 2026-10-08
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.10
P/S
1.56
EV/EBITDA
—
EV/Sales
1.46
ROE
-20.1%
ROA
-13.6%
Div Yield
0.00%
FCF Yield
0.72%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$507.95M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.29M
SI % of Float
3.53%
Days to Cover
2.23
Short Vol Ratio
53.5%
Free Float
36.63M
Float %
87.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-18